Skip to content
Menu

BMO Capital Maintains Market Perform on Integra Lifesciences, Lowers Price Target to $14

Benzinga Newsdesk 1 month ago

Analyst RatingsNewsPrice Target

This page contains a summary, not the full article. Continue to benzinga.com to read the original report.

BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.

BMO Capital analyst Vik Chopra maintains Integra Lifesciences (NASDAQ:IART) with a Market Perform and lowers the price target from $15 to $14.

Read at benzinga.com

← All stock news